Literature DB >> 12543773

Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells.

Frédéric Pouliot1, Alexandre Blais, Claude Labrie.   

Abstract

Bone morphogenetic proteins (BMPs) exert cell type-specific effects on cell proliferation. To clarify the role of the BMP pathway in human breast cancer cells, we used a dominant negative strategy with a truncated human type II BMP receptor (DN-BMPRII; amino acid 1-172) fused to the NH2 terminus of enhanced green fluorescent protein. Transient overexpression of DN-BMPRII interfered with BMP-2-induced Smad1 transcriptional activity and caused cells to accumulate in G1. Stable cell lines that constitutively overexpressed DN-BMPRII were resistant to BMP-2-induced Smad1 phosphorylation and proliferated much more slowly than control stable cell lines. These results suggest that BMPs interacting with type II BMP receptors contribute to the proliferation and/or survival of human breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12543773

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Constitutive activation of BMP signalling abrogates experimental metastasis of OVCA429 cells via reduced cell adhesion.

Authors:  Trevor G Shepherd; Michelle L Mujoomdar; Mark W Nachtigal
Journal:  J Ovarian Res       Date:  2010-02-26       Impact factor: 4.234

2.  Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators.

Authors:  Philip Owens; Michael W Pickup; Sergey V Novitskiy; Anna Chytil; Agnieszka E Gorska; Mary E Aakre; James West; Harold L Moses
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

3.  Comparison of gene expression in hepatocellular carcinoma, liver development, and liver regeneration.

Authors:  Tingting Li; Bingbing Wan; Jian Huang; Xuegong Zhang
Journal:  Mol Genet Genomics       Date:  2010-04-01       Impact factor: 3.291

4.  Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis.

Authors:  Martin Raida; Joachim H Clement; Russell D Leek; Kurosh Ameri; Roy Bicknell; Dietger Niederwieser; Adrian L Harris
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-01       Impact factor: 4.553

Review 5.  Kinase mutations in human disease: interpreting genotype-phenotype relationships.

Authors:  Piya Lahiry; Ali Torkamani; Nicholas J Schork; Robert A Hegele
Journal:  Nat Rev Genet       Date:  2010-01       Impact factor: 53.242

6.  Aggressive melanoma cells escape from BMP7-mediated autocrine growth inhibition through coordinated Noggin upregulation.

Authors:  Mei-Yu Hsu; Sherry A Rovinsky; Chiou-Yan Lai; Shadi Qasem; Xiaoming Liu; Joan How; John F Engelhardt; George F Murphy
Journal:  Lab Invest       Date:  2008-06-16       Impact factor: 5.662

7.  Co-evolution of breast-to-brain metastasis and neural progenitor cells.

Authors:  Josh Neman; Cecilia Choy; Claudia M Kowolik; Athena Anderson; Vincent J Duenas; Sarah Waliany; Bihong T Chen; Mike Y Chen; Rahul Jandial
Journal:  Clin Exp Metastasis       Date:  2013-02-28       Impact factor: 5.150

8.  ΔNp63α-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells.

Authors:  Amanda L Balboni; Justine A Hutchinson; Andrew J DeCastro; Pratima Cherukuri; Karen Liby; Michael B Sporn; Gary N Schwartz; Wendy A Wells; Lorenzo F Sempere; Paul B Yu; James DiRenzo
Journal:  Cancer Res       Date:  2012-12-14       Impact factor: 12.701

9.  Induction of Smad1 by MT1-MMP contributes to tumor growth.

Authors:  Jaclyn A Freudenberg; Wen-Tien Chen
Journal:  Int J Cancer       Date:  2007-09-01       Impact factor: 7.396

10.  Diverse bone morphogenetic protein expression profiles and smad pathway activation in different phenotypes of experimental canine mammary tumors.

Authors:  Helena Wensman; Nils-Erik Heldin; Gunnar Pejler; Eva Hellmén
Journal:  PLoS One       Date:  2009-09-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.